Abstract
Progress in the systemic therapy of thymic malignancies has been hampered in the past by the rarity of this disease entity and the lack of a global collaborative effort in conducting phase II studies. Cisplatin-based therapy has been considered the standard of care, though data typically has been derived from a retrospective case-series approach. However, the arrival of novel cytotoxic agents and molecularly targeted agents into the clinic has helped provide the impetus for improved methodology in thymic malignancy research with an emphasis on more prospective phase II studies. This review discusses the results of traditional cytotoxic agents, novel cytotoxic agents, biologic therapy and the initial evaluation of molecularly targeted therapeutics, such as epidermal growth factor receptor inhibitors, for the treatment of thymic malignancies. In addition, potential novel targets such as VEGF, Bcl-2 and c-KIT are assessed.
Keywords: Thymoma, thymic carcinoma, targeted therapy, chemotherapy
Reviews on Recent Clinical Trials
Title: Systemic Therapeutic Options in Thymic Malignancies: A Glimmer of Hope
Volume: 2 Issue: 3
Author(s): Lisa A. Hammond-Thelin and Charles R. Thomas, Jr.
Affiliation:
Keywords: Thymoma, thymic carcinoma, targeted therapy, chemotherapy
Abstract: Progress in the systemic therapy of thymic malignancies has been hampered in the past by the rarity of this disease entity and the lack of a global collaborative effort in conducting phase II studies. Cisplatin-based therapy has been considered the standard of care, though data typically has been derived from a retrospective case-series approach. However, the arrival of novel cytotoxic agents and molecularly targeted agents into the clinic has helped provide the impetus for improved methodology in thymic malignancy research with an emphasis on more prospective phase II studies. This review discusses the results of traditional cytotoxic agents, novel cytotoxic agents, biologic therapy and the initial evaluation of molecularly targeted therapeutics, such as epidermal growth factor receptor inhibitors, for the treatment of thymic malignancies. In addition, potential novel targets such as VEGF, Bcl-2 and c-KIT are assessed.
Export Options
About this article
Cite this article as:
Hammond-Thelin A. Lisa and Thomas, Jr. R. Charles, Systemic Therapeutic Options in Thymic Malignancies: A Glimmer of Hope, Reviews on Recent Clinical Trials 2007; 2 (3) . https://dx.doi.org/10.2174/157488707781662689
DOI https://dx.doi.org/10.2174/157488707781662689 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Flavonoids on Human Health: Old Subjects but New Challenges
Recent Patents on Biotechnology Synthesis, Computational Study, and Evaluation of In Vitro Antimicrobial, Antibiofilm, and Anticancer Activities of New Sulfanyl Aminonaphthoquinone Derivatives
Letters in Drug Design & Discovery An Overview of Highly Optically Pure Chloramphenicol Bases: Applications and Modifications
Mini-Reviews in Medicinal Chemistry “Care-Getting”: A Conceptual Model of Marshalling Support Near the End of Life
Current Aging Science Decreased Expression and Altered Methylation of Syncytin-1 Gene in Human Placentas Associated with Preeclampsia
Current Pharmaceutical Design NKT Cell Subsets Can Exert Opposing Effects in Autoimmunity, Tumor Surveillance and Inflammation
Current Immunology Reviews (Discontinued) Cdc20: A Potential Novel Therapeutic Target for Cancer Treatment
Current Pharmaceutical Design III. Angiogenesis: Complexity of Tumor Vasculature and Microenvironment
Current Pharmaceutical Design Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders
Current Medicinal Chemistry Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry Targeting Signalling Pathways in Hepatocellular Carcinoma
Current Pharmaceutical Design Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals The Pure Guy – The Scientist
Current Cancer Therapy Reviews Castration-resistant Prostate Cancer: Novel Therapeutics Pre- or Post- Taxane Administration
Current Cancer Drug Targets miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Smart Stimuli Sensitive Nanogels in Cancer Drug Delivery and Imaging: A Review
Current Pharmaceutical Design Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery
Mini-Reviews in Medicinal Chemistry Dietary Lipids and Alzheimer’s Disease
Current Alzheimer Research Dedicated Breast CT: Current Status and New Directions
Current Medical Imaging